Piper Sandler analyst Joseph Catanzaro maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $95 price target.
Piper Sandler Maintains Overweight on Gilead Sciences, Maintains $95 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.